Free Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.71 Average Target Price from Analysts

Arrowhead Pharmaceuticals logo with Medical background

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $43.71.

ARWR has been the subject of a number of research analyst reports. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. B. Riley reiterated a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 6th.

View Our Latest Analysis on Arrowhead Pharmaceuticals

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 40,322 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total value of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares in the company, valued at $40,502,093.85. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $49,000. Van ECK Associates Corp increased its position in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares during the period. CWM LLC raised its stake in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 2,523 shares during the last quarter. Finally, KBC Group NV lifted its position in Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 2,132 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Down 3.0%

Arrowhead Pharmaceuticals stock traded down $0.48 during midday trading on Tuesday, hitting $15.74. 1,219,107 shares of the stock were exchanged, compared to its average volume of 1,529,307. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -3.04 and a beta of 0.96. The stock's 50-day simple moving average is $14.14 and its 200 day simple moving average is $17.29. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to analysts' expectations of $116.27 million. During the same period in the previous year, the firm posted ($1.02) EPS. On average, equities analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

(Get Free Report

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Recommended Stories

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines